公开(公告)号：US20190350932A1

公开(公告)日：2019-11-21

申请号：US16448648

申请日：2019-06-21

申请人： TAIHO PHARMACEUTICAL CO., LTD.

发明人： Akihiro MIURA ,  Hiroshi SOOTOME ,  Junya IWASAKI

IPC分类号： A61K31/519 ,  A61P35/00 ,  A61K31/5383

摘要： It is intended to provide a novel method for treating a cancer using an FGFR inhibitor that exhibits a remarkably excellent antitumor effect and has fewer side effects. The present invention provides a combination preparation for the treatment of a malignant tumor comprising a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof, and one or more additional compound(s) having an antitumor effect or pharmaceutically acceptable salt(s) thereof, and a pharmaceutical composition comprising both the active ingredients. The present invention also provides an antitumor effect enhancer, an antitumor agent, a kit for malignant tumor treatment, etc. comprising a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20230255972A1

公开(公告)日：2023-08-17

申请号：US18015616

申请日：2021-07-14

申请人： TAIHO PHARMACEUTICAL CO., LTD.

发明人： Kei OGUCHI ,  Yuki SHIKATA ,  Junya IWASAKI

IPC分类号： A61K31/519 ,  A61K31/7068 ,  A61K39/395 ,  A61K31/513 ,  A61K33/243 ,  A61K31/337 ,  A61K31/5377 ,  A61K31/565 ,  A61K31/4745 ,  A61K31/436 ,  A61K31/553 ,  A61K31/4375 ,  A61P35/00

CPC分类号： A61K31/519 ,  A61K31/7068 ,  A61K39/3955 ,  A61K31/513 ,  A61K33/243 ,  A61K31/337 ,  A61K31/5377 ,  A61K31/565 ,  A61K31/4745 ,  A61K31/436 ,  A61K31/553 ,  A61K31/4375 ,  A61P35/00

摘要： Provided is a tumor treatment method using a pyrimidine compound or a salt thereof. An antitumor agent that contains a pyrimidine compound represented by general formula (I) or a salt thereof, said antitumor agent being to be administered in combination with another antitumor agent. (In the formula, R1 represents a C1-C4 alkyl group optionally having a C1-C4 alkoxy group as a substituent, or a C3-C4 cycloalkyl group; R2 represents a hydrogen atom, a halogen atom, a C1-C6 alkyl group optionally having, as a substituent(s), one to five C1-C4 alkoxy groups or one to five fluorine atoms, or a C1-C6 alkoxy group; R3 represents a hydrogen atom, or a C1-C4 alkyl group optionally having, as a substituent(s), one to five fluorine atoms; R4 represents a hydrogen atom or a C1-C4 alkyl group; and R5 represents a phenyl group optionally having one to three substituents selected from fluorine atoms and chlorine atoms.)